VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: Results of a multicenter randomized trial of the Greek myeloma study group

Annals of Oncology

Volumn 18, Issue 8, 2007, Pages 1369-1375

  Zervas, K ^a   Mihou, D ^a   Katodritou, E ^a   Pouli, A ^b   Mitsouli, C H ^c   Anagnostopoulos, A ^d   Delibasi, S ^e   Kyrtsonis, M C ^f   Anagnostopoulos, N ^g   Terpos, E ^h   Zikos, P ⁱ   Maniatis, A ^g   Dimopoulos, M A ^d  

^a THEAGENIO CANCER HOSPITAL   (Greece)

^b Agios Savvas Oncological Hospital   (Greece)

^c Metaxa Anti Cancer Institute   (Greece)

^d ALEXANDRA HOSPITAL   (Greece)

^e EVANGELISMOS HOSPITAL   (Greece)

^f LAIKO GENERAL HOSPITAL   (Greece)

^g IASO GENERAL HOSPITAL   (Greece)

^h 251 GENERAL AIR FORCE HOSPITAL   (Greece)

ⁱ UNIVERSITY GENERAL HOSPITAL OF PATRAS   (Greece)

Author keywords

Multiple myeloma; Thalidomide; VAD doxil

Indexed keywords

ACETYLSALICYLIC ACID; DEXAMETHASONE; DOXORUBICIN; LOW MOLECULAR WEIGHT HEPARIN; THALIDOMIDE; VINCRISTINE; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE FREE SURVIVAL; DIZZINESS; DOSE CALCULATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; FEMALE; GREECE; HAND FOOT SYNDROME; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INFECTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROPATHY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RISK BENEFIT ANALYSIS; SIDE EFFECT; SOMNOLENCE; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

EID: 34548173936     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm178     Document Type: Article

References (32)

1. Alexanian R, Haut A, Khan AU et al. Treatment for multiple myeloma, combination chemotherapy with different melphalan dose regimens. J Am Med Assoc 1969; 206: 1680-1685.
2. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan and prednisone as treatment of multiple myeloma: An overview of 6,633 patients from 27 randomized trials. J Clin Oncol 1998; 16: 3832-3842.
3. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 336: 91-97.
4. Badros A, Barlogie B, Siegel E et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 2001; 1114: 600-607.
5. Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 1990, 33: 86-89.
6. Samson D, Gaminara E, Newland A et al. Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet 1989; 2: 882-885.
7. Segeren CM, Sonneveld P. van der Holt B et al. Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma. Br J Haematol 1999; 105: 127-130.
8. Hussein MA, Wood L, Hsi E et al. A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed myeloma patients. Cancer 2002; 95: 2160-2168.
9. Dimopoulos MA, Pouli A, Zervas K et al. Prospective randomized comparison of VAD administered as intravenous bolus injection and VAD with liposomal doxorubicin as first- line treatment in multiple myeloma. Ann Oncol 2003; 14: 1039-1044.
10. Sinhgal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-1571.
11. Hayashi T, Hideshima T, Anderson KC. Novel therapies for multiple myeloma. Br J Haematol 2003; 120: 10-17.
12. Hideshima T. Chauhan D, Shima Y et al. Thalldomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000; 96: 2943-2950.
13. Zervas K, Dimopoulos MA, Hatzicharissi E et al. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxll): A phase II multicenter study. Ann Oncol 2004 15: 134-138.
14. Bladé J, Samson D, Reece D et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated with high-dose therapy and haematopoletic stem cell transplantation. Br J Haematol 1998 102: 1115-1123.
15. Durie BGM, Harousseau JL, Miguel JS et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473.
16. Richardson P, AndersonThalidomide K. dexamethasone: A new standard of care for initial therapy in multiple myeloma. J Clin Oncol 2006; 132: 155-167.
17. Rajkumar SV, Blood E, Vesole D et al. Eastern Cooperative Oncology Group. Phase III clinical trial of thalidomide plus dexamethasone oompared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24: 431-436.
18. Weber D, Rankin K, Gavina M et al. Thalidomide alone or with daxamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21: 16-19.
19. Cavo M, Zamagni E, Tosi P et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005; 106: 35-39.
20. Offidani M, Corvatta L, Piersantelli MN et al. Thalidomide, dexamethasone and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma. Blood 2006; 108: 2159-2164.
21. Hussein MA, Baz R, Srkalovic G et al. Phase 2 study of peglylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone and thalidomide in newly diagnosed and relapsed-rafractory multiple myeloma. Mayo Clin Proc 2006; 81: 889-895.
22. Barlogie B, Tricot G. Complete response in myeloma: A Trojan horse? Blood 2006; 108: 2134.
23. Terpos E, Apperley JF, Samson D et al. Autologous stem cell transplantation in multiple myeloma. Improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single center experience in 127 patients. Bone Marrow Transplant 2003; 31: 163-170.
24. Kumar S, Lacy MQ, Dispenzieri A et al. High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. Bone Marrow Transplant 2004; 34: 161-167.
25. Mileshkin L, Stark R, Day B et al. Development of neuropathy in patients with myeloma treated with thalidomide: Patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 2006; 24: 4507-4514.
26. Dimopoulos MA, Anagnostopoulos A, Weber D. Treatment of plasma cell dyscrasias with thalidomide and its derivatives. J Clin Oncol 2003; 21: 4444-4454.
27. Baz R, Marchant K, Yannaki EO et al. Aspirin decreases the thrombotic complications (DVT) of liposomal doxorubicin, vincristine, decreased frequency dexamethasone & thalidomide (DVd-T) treatment of multiple myeloma. Blood 2004: 104 (Abstr 2397).
28. Tso E, Baz R, Merchant K et al. Aspirin prophylaxis during treatment of multiple myeloma using liposomal doxorubicin, vincristine decreased-frequency dexamethasone & thalidomide decreases post-treatment thrombosis. Proc Am Soc Clin Oncol 2003; 22: 584.
29. Zangari M, Barlogie B, Anassie E et al. Deep venous thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: Effects of prophylactic and therapeutic anticoagulation. Br J Haematol. 2004; 126: 715-721.
30. Palumbo A, Bringhen S, Caravita T et al. Oral melphalan and prednisone chemotheraphy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomized controlled trial. Lancet 2006; 367: 825-831.
31. Harousseau JL, Attal M, Leleu X et al. Bortezomib plus daxamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: Results of an IFM phase II study. Haematologica 2006; 91: 1498-1505.
32. Rajkumar SV, Hayman SR, Lacy MQ et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005; 108: 4050-4053.